QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Three separate studies were undertaken in HIV-1 uninfected persons to determine if the adjuvant QS-21 improves the magnitude or kinetics of immune responses induced by recombinant soluble gp120 HIV-1(MN) protein (rsgp120) immunization. The QS-21 was administered at two doses (50 and 100 microg), either alone or in combination with aluminum hydroxide (600 microg). At the highest doses of rsgp120 (100, 300, and 600 microg), QS-21 exerted no significant effect on either binding or neutralizing antibody titers. Antibody binding and neutralizing responses fell dramatically when rsgp120, formulated with alum alone, was given at low doses (3 and 30 microg). In contrast, antibody responses similar in titer to those in the high dose antigen groups were induced with the low dose rsgp120 formulated with QS-21. In addition, the lymphocyte proliferation and delayed type hypersensitivity skin testing were superior in the QS-21 recipients compared with the alum recipients at the low antigen doses. Moderate to severe pain was observed in majority of the volunteers receiving QS-21 formulations, and vasovagal episodes and hypertension were not infrequent. Thus, the use of QS-21 may provide a means to reduce the dose of a soluble protein immunogen.
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
T G
TG
Evans
M J
MJ
McElrath
T
T
Matthews
D
D
Montefiori
K
K
Weinhold
M
M
Wolff
M C
MC
Keefer
E G
EG
Kallas
L
L
Corey
G J
GJ
Gorse
R
R
Belshe
B S
BS
Graham
P W
PW
Spearman
D
D
Schwartz
M J
MJ
Mulligan
P
P
Goepfert
P
P
Fast
P
P
Berman
M
M
Powell
D
D
Francis
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000302:isolation & purification; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000536:Aluminum Hydroxide / Q000008:administration & dosage; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D015483:HIV Antibodies / Q000096:biosynthesis; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage* / Q000302:isolation & purification; D006801:Humans; D006968:Hypersensitivity, Delayed; D007114:Immunization; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008875:Middle Aged; D012449:Safety; D012503:Saponins / Q000008:administration & dosage*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000302:isolation & purification
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D012503:Saponins; D014614:Vaccines, Synthetic; D000536:Aluminum Hydroxide; C078785:saponin QA-21V1